Galera Therapeutics, Inc.
GRTX
$0.0235
-$0.0004-1.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -51.82% | -56.34% | -50.06% | -11.30% | 12.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -69.86% | -67.78% | -55.92% | -27.54% | -8.35% |
| Operating Income | 69.86% | 67.78% | 55.92% | 27.54% | 8.35% |
| Income Before Tax | 67.57% | 71.59% | 58.84% | 29.13% | 5.15% |
| Income Tax Expenses | -- | -190.00% | -- | -- | -- |
| Earnings from Continuing Operations | 67.91% | 71.85% | 58.80% | 29.05% | 5.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.91% | 71.85% | 58.80% | 29.05% | 5.05% |
| EBIT | 69.86% | 67.78% | 55.92% | 27.54% | 8.35% |
| EBITDA | 69.73% | 68.17% | 56.28% | 27.87% | 8.65% |
| EPS Basic | 75.57% | 80.99% | 72.75% | 55.14% | 38.19% |
| Normalized Basic EPS | 82.37% | 82.44% | 75.13% | 57.48% | 40.46% |
| EPS Diluted | 75.57% | 80.99% | 72.78% | 55.19% | 38.32% |
| Normalized Diluted EPS | 82.37% | 82.44% | 75.13% | 57.48% | 40.46% |
| Average Basic Shares Outstanding | 22.79% | 43.57% | 57.02% | 68.84% | 64.28% |
| Average Diluted Shares Outstanding | 22.79% | 43.57% | 57.02% | 68.84% | 64.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |